ArcticZymes has entered into an agreement with ReiThera to supply its SAN product for ReiThera’s COVID-19 vaccine candidate

Tromsø, 02 July, 2020:  ArcticZymes AS (OSE:AZT), a subsidiary of ArcticZymes Technologies ASA, announces that it has entered into a supply agreement with vaccine specialist ReiThera Srl (Rome, Italy) for the supply of Salt Active Nuclease (SAN-HQ) to be used in the development and manufacturing of ReiThera’s novel vaccine candidate against COVID-19. The vaccine candidate, which is based on ReiThera’s …

Biotec Pharmacon ASA rebrands as ArcticZymes Technologies ASA

Tromsø, Norway, 17. June 2020 – Biotec Pharmacon (OSE: BIOTEC) announces it has officially rebranded to ArcticZymes Technologies. As previously announced and decided by the Annual General Meeting, Biotec Pharmacon ASA has formally changed its name to ArcticZymes Technologies ASA. The new name is formally registered with Brønnøysundregistrene and will trade under the new ticker “AZT” over the next days. …

ArcticZymes granted NOK 1.6 million funding from Innovation Norway for enzyme development project.

Tromsø, Norway, 28. May 2020 – Biotec Pharmacon (OSE: Biotec) announces its subsidiary, ArcticZymes AS, has been granted by Innovation Norway up to NOK 1.6 million for a project to commercialize additional enzyme components required by diagnostic developers. ArcticZymes Cod UNG enzyme offers diagnostic developers a superior enzyme-based solution for preventing false-positive results without affecting sensitivity in molecular diagnostic tests. …